Trial Profile
A Phase 3, Multicenter, Randomized, Double-Blind Study With an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Bimekizumab (Primary) ; Adalimumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms BE SURE
- Sponsors UCB; UCB Biopharma
- 09 Mar 2024 Results of pooled analysis((BE SURE, BE VIVID, and BE READY) announced in presentations of BIMZELX (bimekizumab-bkzx) four-year efficacy and safety data in the treatment of adults with moderate to severe plaque psoriasis are being shared this week at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, March 8 to 12, in the UCB Media Release.
- 10 Nov 2023 Results of pooled analysis from NCT03412747, NCT03370133, NCT03410992, NCT03598790 assessing bimekizumab's 3-year safety profile in patients with moderate to severe plaque psoriasis published in the British Journal of Dermatology
- 18 Oct 2023 According to an UCB media release, the Food and Drug Administration (FDA) has approved Bimzelx (bimekizumab-bkzx) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.